Longitudinal and cross-sectional variability in markers of joint metabolism in patients with knee pain and articular cartilage abnormalities

Osteoarthritis and Cartilage

Volumn 6, Issue 5, 1998, Pages 351-361

  Lohmander, L Stefan ^a   Dahlberg, Leif ^a   Eyre, David ^b   Lark, Michael ^c   Thonar, Eugene J M A ^d   Ryd, Leif ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d RUSH MEDICAL COLLEGE   (United States)

Author keywords

Joint fluid markers; Knee; Osteoarthritis

Indexed keywords

ARTHRALGIA; ARTICLE; ARTICULAR CARTILAGE; DISEASE MARKER; HUMAN; METABOLISM; PRIORITY JOURNAL; SYNOVIAL FLUID LEVEL; TREATMENT OUTCOME;

EID: 0032170469     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1053/joca.1998.0134     Document Type: Article

References (51)

1. 1. Lohmander LS. Articular Cartilage and Osteoarthrosis - The role of molecular markers to monitor breakdown, repair and disease. J Anat 1994;184:477-92.
2. 2. Poole AR. Immunochemical markers of joint inflammation, skeletal damage and repair; where are we now? Ann Rheum Dis 1994;53:3-5.
3. 3. Saxne T, Heinegård D. Matrix proteins: potentials as body fluid markers of changes in the metabolism of cartilage and bone in arthritis. J Rheumatol 1995;22:71-4.
4. 4. Lohmander LS, Saxne T, Heinegård D. Molecular markers of joint and skeletal diseases. Acta Orthop Scand 1995;66(suppl 266).
5. 5. Lohmander LS. What is the current status of biochemical markers in the diagnosis, prognosis and monitoring of osteoarthritis? Baillieres Clin Rheumatol 1997;11:423-38.
6. 6. Lohmander LS, Felson D. Defining and validating the clinical role of molecular markers in osteoarthritis. In: Brandt KD, Doherty M, Lohmander LS, editors. Osteoarthritis. Oxford: Oxford University Press; 1998. p. 519-30.
7. 7. Wallis WJ, Simkin PA, Nelp WB. Protein traffic in human synovial effusions. Arthritis Rheum 1987;30:57-63.
8. 8. Levick JR. Synovial fluid. Determinants of volume turnover and material concentration. In: Kuettner KE, Schleyerbach R, Peyron JG, Hascall VC, editors. Articular cartilage and osteoarthritis. New York: Raven Press; 1992. p. 529-41.
9. 9. Simkin PA, Bassett JE. Cartilage matrix molecules in serum and synovial fluid. Curr Opin Rheumatol 1995;7:346-51.
10. 10. Dahlberg L, Ryd L, Heinegård D, Lohmander LS. Proteoglycan fragments in joint fluid - influence of arthrosis and inflammation. Acta Orthop Scand 1992;63:417-23.
11. 11. Pejovic M, Stankovic A, Mitrovic DR. Determination of the apparent synovial permeability in the knee joints of patients suffering from osteoarthritis and rheumatoid arthritis. Br J Rheumatol 1995;34:520-4.
12. 12. Myers SL, O'Connor BL, Brandt KD. Accelerated clearance of albumin from the osteoarthritic knee: implications for interpretation of concentrations of "cartilage markers" in synovial fluid. J Rheumatol 1996;23:1744-8.
13. 13. Thonar EJ-MA, Lenz ME, Klintworth GK, Caterson B, Pachman LM, Glickman P, et al. Quantification of keratan sulfate in blood as a marker of cartilage catabolism. Arthritis Rheum 1985;28:1367-76.
14. 14. Saxne T, Heinegård D, Wollheim FA. Cartilage proteoglycans in synovial fluid and serum in patients with inflammatory joint disease. Arthritis Rheum 1987;30:972-9.
15. 15. Poole AR, Ionescu M, Swan A, Dieppe PA. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan - implications for pathogenesis. J Clin Invest 1994;94:25-33.
16. 16. Spector TD, Woodward L, Hall GM, Hammond A, Williams A, Butler MG, et al. Keratan sulphate in rheumatoid arthritis, osteoarthritis, and inflammatory diseases. Ann Rheum Dis 1992;51:1134-7.
17. 17. Lohmander LS, Thonar EJ-MA. Serum keratan sulfate concentrations are different in primary and posttraumatic osteoarthrosis of the knee. Trans Orthop Res Soc (abstract) 1994;19:459.
18. 18. Lohmander LS, Saxne T, Heinegård D. Release of cartilage oligomeric matrix protein (COMP) into joint fluid after injury and in osteoarthrosis. Ann Rheum Dis 1994;53:8-13.
19. 19. Lohmander LS, Hoerrner LA, Lark MW. Metalloproteinases, tissue inhibitor and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum 1993;36:181-9.
20. 20. Lohmander LS, Hoerrner LA, Dahlberg L, Roos H, Björnsson S, Lark MW. Stromelysin, tissue inhibitor and proteoglycan fragments in human knee joint fluid after injury. J Rheumatol 1993;20:1362-8.
21. 21. Lohmander LS, Yoshihara Y, Roos H, Kobayashi T, Yamada H, Shinmei M. Procollagen II C-propeptide in joint fluid. Changes in concentrations with age, time after joint injury and osteoarthritis. J Rheumatol 1996;23:1765-9.
22. 22. Petersson IF, Sandquist L, Svensson B, Saxne T. Cartilage markers in synovial fluid in symptomatic knee osteoarthritis. Ann Rheum Dis 1997;56:64-7.
23. 23. Belcher C, Yaqub R, Fawthrop F, Bayliss M, Doherty M. Synovial fluid chondroitin and keratan sulphate epitopes; glycosaminoglycans; and hyaluronan in arthritic and normal knees. Ann Rheum Dis 1997;56:299-307.
24. 24. Lohmander LS, Roos H, Dahlberg L, Lark MW. The role of molecular markers to monitor disease, intervention and cartilage breakdown in osteoarthritis. Acta Orthop Scand 1995;66:84-7.
25. 25. Dahlberg L, Lohmander LS, Ryd L. Intra-articular injections of Hyaluronan in patients with early stage osteoarthritis of the knee. Arthritis Rheum 1994;37:521-8.
26. 26. Cooke TDV, Scudamore RA, Bryant JT, Sorbie C, Siu D, Fischer B. A quantitative approach to radiography of the lower limb. Principles and applications. J Bone Joint Surg (Br) 1991;73-B:715-20.
27. 27. Ahlbäck S. Osteoarthrosis of the knee: a radiographic investigation. Acta Radiol Suppl 1968;277:7-72.
28. 28. van Valburg AA, Wenting MJ, Beekman B, Te Koppele JM, Lafeber FP, Bijlsma JW. Degenerated human articular cartilage at autopsy represents preclinical osteoarthritic cartilage: comparison with clinically defined osteoarthritic cartilage. J Rheumatol 1997;24:358-64.
29. 29. Outerbridge RE. The etiology of chondromalacia patellae. J Bone Joint Surg 1961;43-B:752-7.
30. 30. Björnsson S. Simultaneous preparation and quantitation of proteoglycans by precipitation with Alcian Blue. Anal Biochem 1993;210:282-91.
31. 31. Møller HJ, Larsen FS, Ingemann-Hansen T, Poulsen JH. ELISA for the core protein of the large cartilage aggregating proteoglycan, aggrecan: comparison with the concentrations of immunogenic keratan sulphate in synovial fluid, serum and urine. Clin Chim Acta 1994;225:43-55.
32. 32. Lohmander LS, Ionescu M, Jugessur H, Poole AR. Changes in joint cartilage aggrecan metabolism after knee injury and in osteoarthritis. Arthritis Rheum 1998; in press.
33. 33. Cooksley S, Hipkiss JB, Tickle SP, Holmesievers E, Docherty AJP, Murphy G, et al. Immunoassays for the detection of human collagenase; stromelysin; tissue inhibitor of metalloproteinases (TIMP) and enzyme-inhibitor complexes. Matrix 1990;10:285-91.
34. 34. Walakovits LA, Moore VL, Bhardwaj N, Gallick GS, Lark MW. Detection of high levels of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and post-traumatic knee injury. Arthritis Rheum 1991;35:35-42.
35. 35. Thonar EJ-MA, Meyer RF, Dennis RF, Lenz ME, Maldonado B, Hassell JR, Hewitt AT, Stark WJ, Stock EL, Kuettner KE, Klintworth GK. Absence of normal keratan sulfate in the blood of patients with macular corneal dystrophy. Amer J Ophthalmol 1986;102:561-69.
36. 36. Williams JM, Downey C, Thonar EJ-MA. Increase in levels of serum keratan sulfate following cartilage proteoglycan degradation in the rabbit knee joint. Arthritis Rheum 1988;31:557-60.
37. 37. Hanson DA, Weis MAE, Bollen A-M, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7:1251-8.
38. 38. Christensson B, Ryd L, Dahlberg L, Lohmander LS. Candida albicans arthritis after multiple intra-articular injections in a non-immunocompromised patient. Acta Orthop Scand 1993;64:695-8.
39. 39. Cohen J. Statistical Power Analysis for the Behavioural Sciences. New York: Academic Press 1977:1-27.
40. 40. Thonar EJ-MA, Shinmei M, Lohmander LS. Body Fluid Markers of Cartilage Changes in Osteoarthritis. Rheumatic Diseases Clinics of North America 1993;19:635-57.
41. 41. Delmas PD. Biochemical markers of bone turnover. Acta Orthop Scand 1995;66(suppl 266):176-82.
42. 42. Eyre D. The specificity of collagen cross-links as markers of bone and connective tissue degradation. Acta Orthop Scand 1995;66(suppl 266):166-70.
43. 43. Robins SP. Collagen crosslinks in metabolic bone disease. Acta Orthop Scand 1995;66(suppl 266):171-5.
44. 44. Clemens JD, Herrick MV, Singer FR, Eyre DR. Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem 1997;43:2058-63.
45. 45. Dahlberg L, Fridén T, Roos H, Lark MW, Hoerrner LA, Lohmander LS. Longitudinal study of cartilage matrix metabolism in patients with cruciate ligament rupture - synovial fluid concentrations of aggrecan fragments, stromelysin-1 and tissue inhibitor of metalloproteinase-1. Br J Rheumatol 1994;33:1107-11.
46. 46. Kobayashi T, Yoshihara Y, Samura A, Yamada H, Shinmei M, Roos H, et al. Synovial fluid levels of the C-propeptide of type II collagen correlate with body mass index in primary knee osteoarthritis. Ann Rheum Dis 1997;56:500-3.
47. 47. Roos H, Dahlberg L, Hoerrner LA, Lark MW, Thonar EJ-MA, Shinmei M, et al. Markers of cartilage matrix metabolism in human joint fluid and serum - The effect of exercise. Osteoarthritis Cartilage 1995;3:7-14.
48. 48. Thonar EJ-MA, Pachman LM, Lenz ME, Hayford J, Lynch P, Kuettner KE. Age related changes in the concentration of serum keratan sulphate in children. J Clin Chem Clin Biochem 1988;26: 57-63.
49. 49. Campion GV, McCrae F, Schnitzer TJ, Lenz ME, Dieppe PA, Thonar EJ. Levels of keratan sulfate in the serum and synovial fluid of patients with osteoarthritis of the knee. Arthritis Rheum 1991;34:1254-9.
50. 50. Saxne T, Heinegård D. Synovial fluid analysis of two groups of proteoglycan epitopes distinguishes early and late cartilage lesions. Arthritis Rheum 1992;35:385-90.
51. 51. Thonar EJ-MA, Manicourt DH, Lenz ME, Williams JM, Masuda K, Wang L, Kuettner KE. Serum markers of cartilage changes in osteoarthritis. In: Kuettner KE, Goldberg VM, editors. Osteoarthritic Disorders. Illinois, American Academy of Orthopaedic Surgeons, 1995. p. 445-58.